Immupharma PLC - 2026 RESULT OF ANNUAL GENERAL MEETING

RNS: RELEASE
ImmuPharma PLC
("ImmuPharma" or the "Company")
2026 RESULT OF ANNUAL GENERAL MEETING
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today. The Company is pleased to announce that six of the six resolutions (Resolutions 1 - 6 inclusive) were duly passed by shareholders. Details are contained in the table below.
|
Resolution |
For |
% For |
Against |
% Against |
Withheld |
|
1. To receive the accounts of the Company for the year ended |
163,496,678 |
99 |
2,252,180 |
1 |
365,965 |
|
2. To re-appoint Ketan Patel as a director of the Company |
156,211,793 |
98 |
3,080,916 |
2 |
6,822,114 |
|
3. To re-appoint Crowe UK LLP as Auditor of the Company |
163,482,368 |
99 |
2,311,240 |
1 |
321,215 |
|
4. That the directors be authorised for the purpose of Section 551 of the Companies Act 2006 (the "Act") to allot shares on the basis as set out in the Notice of Meeting |
152,641,450 |
94 |
11,960,794 |
6 |
1,512,579 |
|
SPECIAL RESOLUTION 5. That the directors be authorised for the purpose of Section 551 of the Companies Act 2006 (the "Act") to allot shares on the basis as set out in the Notice of Meeting |
151,322,867 |
93 |
13,507,185 |
7 |
1,284,771 |
|
SPECIAL RESOLUTION |
155,666,377 |
96 |
7,767,242 |
4 |
2,681,204 |
As at the date of the AGM, the number of issued ordinary shares of the Company was 623,911,379 shares, which was the total number of shares entitling the holders to attend and vote for or against all resolutions. In accordance with the Company's Articles of Association, every member has one vote for every share held. Votes withheld are not votes in law and have not been counted in the calculation of the proportion of vote "for" or "against" a resolution. Proxy appointments which gave discretion to the Chairman have been included in the "for" total.
Ends
|
For further information please contact:
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptidebased therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives.
For additional information about ImmuPharma please visit www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not registered in any category of registration under the securities legislation of any province or territory of Canada. Nothing in this record constitutes "advice" concerning investing in, buying, or selling a security within the meaning of applicable Canadian securities legislation. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after obtaining advice from a registrant authorised under the securities legislation of your province or territory.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship is for news distribution and media services only and does not determine, influence, or shape the editorial content produced.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE